Introduction
============

Stroke among atrial fibrillation (AF) patients has been shown to be associated with increased severity, functional disability, and mortality compared with patients without AF.^[@b1]^ While stroke‐related costs have been estimated among a general population,^[@b2]^ limited data exist on the economic implications of stroke among patients with AF. In this retrospective study, we estimate the cost of ischemic stroke (IS), hemorrhagic stroke (HS), and transient ischemic attack (TIA) among patients with AF versus those without AF from a third‐party payer perspective. These data will provide a baseline estimate on the economic burden of stroke to inform future cost‐benefit evaluation of interventions aimed at preventing stroke in AF patients.

Methods
=======

Data Source
-----------

This study used administrative claims data from the Truven Health Analytics MarketScan^®^ Research Databases (Commercial and Medicare Supplemental), 2005‐2011. The commercial database includes data from 150 contributing large self‐insured employers. The Medicare Supplemental database contains the healthcare experience of individuals with Medicare supplemental insurance paid by employers. Approximately 40 million lives were analyzed, allowing for a nationally representative sample of Americans with employer‐provided health insurance.

Patient Selection
-----------------

We identified adult patients (≥18 years of age) with at least 1 primary inpatient diagnosis of stroke or TIA (International Classification Modification \[ICD‐9‐CM\]: 430.xx, 431.xx, 432.xx for hemorrhagic; 433.01, 433.11, 433.31, 434.xx for ischemic; 435.8, 435.9 for TIA)^[@b2]--[@b6]^ or at least 1 emergency department diagnosis of TIA between January 1, 2006 and November 1, 2011. The date of the first identified stroke or TIA diagnosis constituted the index date. Patients could not have had a stroke or TIA diagnosis in the 12 months prior to the index stroke (ie, to ensure a "baseline period" without stroke or TIA) and were required to be continuously eligible for 12 months prior to the index stroke event.

Presence of AF was based on ≥1 inpatient or ≥2 outpatient claims (separated by \<1 year) associated with an AF diagnosis (ICD‐9‐CM: 427.31)^[@b7]--[@b8]^ in the baseline period and up to 3 months after index stroke event to allow inclusion of patients who were identified to have AF after stroke occurrence.

Study Measures
--------------

The following baseline demographic and clinical characteristics were evaluated---age, sex, geographic region, metropolitan statistical area, year of index stroke diagnosis, type of stroke or TIA, comorbidities, use of oral anticoagulants (ie, warfarin, dabigatran, and rivaroxaban), inpatient and ED resource use, and duration of follow‐up.

Outcomes included index hospitalization length of stay (LOS), index event costs (all costs occurring throughout the timeframe of the index hospitalization or ED visit), hospitalization rates within 30 days of index event, stroke‐related hospitalization rates 12 months post‐index, and stroke‐related costs 12 months post‐index for all components of medical care. Stroke‐related costs and hospitalizations were required to list a stroke/TIA ICD‐9‐CM code.

Costs data reflect the total gross payments to all providers associated with a given medical event. Total stroke‐related costs were derived by summing all payments associated with a stroke/TIA admission (based on primary or any ICD‐9‐CM diagnosis code) over the 12‐month follow‐up period for all places of service (eg, inpatient, outpatient, emergency department, skilled nursing facility, home health care, durable medical equipment). Stroke‐related laboratory and pharmacy costs (ie, the presence of select medications, including anticoagulants such as warfarin, dabigatran, and rivaroxaban, as well as antiplatelets and rate/rhythm control medications) were included in the calculation of total costs.

Follow‐up analysis included those patients who were continuously enrolled for 12 months following the index event.

Statistical Analyses
--------------------

We compared adjusted index event LOS and stroke‐related cost between patients with and without AF using a generalized linear model with a negative binomial distribution and a log link, controlling for age, sex, geography, year of index diagnosis, selected comorbidities (based on \>5% frequency), oral anticoagulant (OAC) use, and baseline hospital and ED use. Given common characteristics observed in healthcare cost data, such as a highly skewed distribution from the small percentage of patients with extremely high expense rates, the generalized linear model is highly recommended for models using administrative claims data.^[@b9]^ Regression coefficients from the generalized linear model help to quantify the relationship between 12‐month stroke‐related costs and the selected patient characteristics (eg, when exponentiated using a base of *e*, the coefficient represents a percentage increase/decrease in costs compared to patients without the characteristic). Adjusted stroke‐related hospitalization rates were estimated using a logistic regression controlling for the same covariates included in the generalized linear model.

Results
=======

We identified 160 456 patients with stroke or TIA, 23 807 (14.8%) of whom had AF ([Table 1](#tbl01){ref-type="table"}). Of the AF patients, 43.5% were on an oral‐anticoagulant in the baseline period. There were differences in terms of demographic and clinical characteristics between the AF and non‐AF groups. In the AF cohort, mean age was 77 years (±11.6) compared to a mean age of 67 years (±14.8) in the non‐AF cohort (*P*\<0.01) ([Table 1](#tbl01){ref-type="table"}). Prevalence of selected comorbidities was also higher in the AF cohort (*P*\<0.01).

###### 

Baseline Characteristics

  Characteristic                                                   Overall         AF Cohort       Non‐AF Cohort   *P* Value[\*](#tf1-1){ref-type="table-fn"}
  ---------------------------------------------------------------- --------------- --------------- --------------- --------------------------------------------
  Number of subjects                                               160 456         23 807          136 649         
  Age, y                                                                                                           
  Mean, SD                                                         69 (±14.8)      77 (±11.6)      67 (±14.8)      \<0.0001
  Age group                                                                                                        
  \<55, N (%)                                                      29 572 (18.4)   1048 (4.4)      28 560 (20.9)   
  55 to 64, N (%)                                                  39 376 (24.6)   3285 (13.8)     36 075 (26.4)   
  65+, N (%)                                                       91 508 (57.0)   19 474 (81.8)   72 014 (52.7)   
  Female, %                                                        51.5            50.7            51.6            0.0121
  Geographic Region, %                                                                                             
  Northeast                                                        12.8            15.3            12.4            \<0.0001
  North Central                                                    34.6            35.3            34.4            
  West                                                             17.1            19.7            16.7            
  South                                                            35.3            29.5            36.3            
  Unknown                                                          0.2             0.3             0.2             
  Metropolitan statistical area, %                                 84.0            84.0            82.9            \<0.0001
  Stroke Type, %                                                                                                   
  Ischemic                                                         49.9            59.9            48.2            \<0.0001
  TIA                                                              36.2            27.3            37.8            
  Hemorrhagic                                                      13.9            12.8            14.1            
  Type of Hemorrhagic Stroke[\*](#tf1-2){ref-type="table-fn"}, %                                                   
  Subarachnoid                                                     25.3            8.9             27.9            
  Intracerebral                                                    51.2            58.4            50.0            
  Other and unspecified intracranial                               23.5            32.6            22.0            
  Selected Comorbidities (\>5% frequency, %)                                                                       
  Chronic obstructive pulmonary disease                            9.7             15.0            8.8             \<0.0001
  Congestive heart failure (excluding left ventricular)            9.0             24.1            6.4             \<0.0001
  Diabetes mellitus                                                24.6            26.9            24.2            \<0.0001
  Hypertension                                                     51.2            62.1            49.3            \<0.0001
  Malignancy                                                       13.9            19.1            13.0            \<0.0001
  Peripheral vascular disease                                      9.6             15.2            8.6             \<0.0001
  OAC use, %                                                       10.2            43.5            4.4             \<0.0001

AF indicates atrial fibrillation; OAC, oral anticoagulant; TIA, transient ischemic attack; SD, standard deviation.

Fisher\'s exact or Wilcoxon test.

Type of hemorrhagic stroke was not tested.

Source: Truven MarketScan^®^ Research Databases January 1, 2005 to December 31, 2011.

In the overall sample, 49.9% of patients had IS, 13.9% had HS, and 36.2% had TIA (12.2% identified with ED; 24.0% identified with hospitalization). Compared to the non‐AF cohort, the AF cohort had higher rates of IS, intracerebral hemorrhage, and other intracranial hemorrhage and lower rates of TIA and subarachnoid hemorrhage ([Table 1](#tbl01){ref-type="table"}).

Among IS and TIA patients, the AF cohort had longer index hospitalization LOS than the non‐AF cohort (8.3 versus 7.9 for IS; 4.1 versus 3.4 for TIA), but the opposite was true for HS patients (10.7 versus 14.1 days). Among patients surviving the index event, hospitalization within 30 days of discharge was significantly more common among AF patients, regardless of index stroke type (OR=1.248 *P*\<0.05 for IS; OR=1.424 *P*\<0.05 for HS; OR=1.425 *P*\<0.05 for TIA).

Unadjusted mean cost of index event was \$20 933 (±\$37 413) for IS, \$59 054 (±\$99 512) for HS, \$8616 (±10 812) for TIA with index hospitalization, and \$3395 (±3862) for TIA with index ED visit ([Table 2](#tbl02){ref-type="table"}). Adjusted mean incremental costs (index plus 12‐month post‐index) for AF patients were significantly higher than those for non‐AF patients by: \$4726, \$7824, and \$1890 for index IS, HS, TIA (identified by hospitalization), respectively, and \$1700 for TIA (identified by ED) (all *P*\<0.01). In the multivariate regression predicting stroke‐related follow‐up costs (index plus 12‐month post‐index), AF was associated with significant increases in total stroke‐related costs among patients with IS (20%), HS (13%), and TIA (19%) (all *P*\<0.01) ([Table 3](#tbl03){ref-type="table"}).

###### 

Index Hospitalization and Post‐Index Stroke‐related Costs Among AF and Non‐AF Patients

  Stroke Type/Measure                                                                   Overall   AF Cohort             Non‐AF Cohort   Difference (AF vs Non‐AF)                                                        
  ------------------------------------------------------------------------------------- --------- --------------------- --------------- --------------------------- -------- --------------------- ------------ -------- ----------
  Ischemic Stroke                                                                                                                                                                                                        
  Index event LOS, days                                                                 80 083    8.0 (±11.5)           14 251          8.3 (±11.7)                 65 832   7.9 (±11.4)           0.4          1.1      0.0005
  Index mortality rate, %                                                                         3.4                                   5.6                                  2.9                   2.7          1.1      0.0011
  Patients surviving index hospitalization                                              77 376                          13 453                                      63 923                                               
  Hospitalization within 30 days, %                                                               6.5                                   6.9                                  6.4                   0.5          1.4      \<0.0001
  Patients with continuous enrollment 12 months post‐index                              46 071                          7072                                        38 999                                               
  Stroke‐related hospitalization within 12 months[\*](#tf2-1){ref-type="table-fn"}, %             11.6                                  12.3                                 11.5                  0.8          0.7      0.1325
  Mean cost index event                                                                 80 083    \$20 933 (±37 413)    14 251          \$21 151 (±36 553)          65 832   \$20 886 (±37 597)    \$265        \$3520   \<0.0001
  Mean 12‐month total stroke‐related cost[\*](#tf2-1){ref-type="table-fn"}              46 071    \$25 106 (±39 475)    7072            \$26 602 (±41 772)          38 999   \$24 835 (±39 039)    \$1767       \$4726   \<0.0001
  Hemorrhagic Stroke                                                                                                                                                                                                     
  Index event LOS, days                                                                 22 275    13.7 (±20.1)          3052            10.7 (±16.1)                19 223   14.1 (±20.6)          −3.4         1.0      \<0.0001
  Index mortality, %                                                                              18.3                                  23.1                                 17.6                  5.5          −1.3     0.1436
  Patients surviving index hospitalization                                              18 185                          2346                                        15 839                                               
  Hospitalization within 30 days, %                                                               9.7                                   10.0                                 9.6                   0.4          2.8      0.0001
  Patients with continuous enrollment 12 months post‐index                              10 010                          1162                                        8848                                                 
  Stroke‐related hospitalization within 12 months[\*](#tf2-1){ref-type="table-fn"}, %             14.9                                  16.5                                 14.7                  1.8          1.4      0.3179
  Mean cost index event                                                                 22 275    \$59 054 (±99 512)    3052            \$38 028 (±66 693)          19 223   \$62 384 (±103 371)   (\$24 356)   \$2799   0.0214
  Mean 12‐month total stroke‐related cost[\*](#tf2-1){ref-type="table-fn"}              10 010    \$74 462 (±113 962)   1162            \$54 268 (±79 585)          8848     \$77 113 (±117 479)   (\$22 845)   \$7824   0.0019
  TIA                                                                                                                                                                                                                    
  Patients with hospitalization index event                                                                                                                                                                              
  Index event LOS, days                                                                 38 585    3.5 (±4.0)            4759            4.1 (±3.7)                  33 826   3.4 (±4.1)            0.7          0.3      \<0.0001
  Index mortality, %                                                                              0.1                                   0.2                                  0.1                   0.1          N/A      N/A
  Patients surviving index hospitalization                                              38 541                          4749                                        33 792                                               
  Hospitalization within 30 days, %                                                               3.2                                   5.0                                  2.9                   2.1          1.2      \<0.0001
  Patients with continuous enrollment 12 months post‐index                              26 604                          3047                                        23 557                                               
  Stroke‐related hospitalization within 12 months[\*](#tf2-1){ref-type="table-fn"}, %             8.0                                   10.2                                 7.7                   2.5          1.1      0.0520
  Mean cost index event                                                                 38 585    \$8616 (±10 812)      4759            \$9208 (±4800)              33 826   \$8533 (±10 128)      \$675        \$846    \<0.0001
  Mean 12‐month total stroke‐related cost[\*](#tf2-1){ref-type="table-fn"}              26 604    \$11 931 (±15 617)    3047            \$13 581 (±17 064)          23 557   \$11 718 (±15 407)    \$1863       \$1890   \<0.0001
  Patients With ED Index Event                                                                                                                                                                                           
  Hospitalization within 30 days, %                                                     19 513    8.3                   1745            13.8                        17 768   7.8                   6.0          5.0      \<0.0001
  Patients with continuous enrollment 12 months post‐index                              12 956                          1082                                        11 874                                               
  Stroke‐related hospitalization within 12 months[\*](#tf2-1){ref-type="table-fn"}, %             8.9                                   14.5                                 8.4                   6.1          5.9      \<0.0001
  Mean cost index event                                                                 19 513    \$3395 (±3862)        1745            \$2960 (±3858)              17 768   \$3438 (±3860)        (\$478)      \$274    0.0011
  Mean 12‐month total stroke‐related cost[\*](#tf2-1){ref-type="table-fn"}              12 956    \$9096 (±14 091)      1082            \$9651 (±15 531)            11 874   \$9046 (±13 952)      \$605        \$1700   \<0.0001

AF indicates atrial fibrillation; ED, emergency department; TIA, transient ischemic attack; LOS, length of stay.

Only patients with 12 months continuous enrollment post index; includes index event cost.

Source: Truven MarketScan^®^ Research Databases January 1, 2005 to December 31, 2011.

###### 

Generalized Linear Model Predicting Stroke‐Related Costs in the 12 Months Following the Index Event, by Stroke Type

  Stroke Type                                                             Ischemic Stroke[\*](#tf3-1){ref-type="table-fn"}   Hemorrhagic Stroke[\*](#tf3-2){ref-type="table-fn"}   TIA[\*](#tf3-3){ref-type="table-fn"}                                                                 
  ----------------------------------------------------------------------- -------------------------------------------------- ----------------------------------------------------- -------------------------------------- ------------- ------------- ---------- ------------- -------- ----------
  Intercept                                                               10.392                                             0.0209                                                \<0.0001                               11.048        0.0548        \<0.0001   9.2636        0.02     \<0.0001
  AF cohort                                                               **0.1847**                                         0.0125                                                \<0.0001                               **0.1179**    0.038         0.0019     **0.1717**    0.0147   \<0.0001
  Hemorrhage Subtype (vs Other and unspecified intracranial hemorrhage)                                                                                                                                                                                                                 
  Subarachnoid hemorrhage                                                 ---                                                ---                                                   ---                                    **0.7295**    0.0301        \<0.0001   ---           ---      ---
  Intracerebral hemorrhage                                                ---                                                ---                                                   ---                                    **0.1843**    0.0255        ---        ---           ---      
  Age Group (vs \<55)                                                                                                                                                                                                                                                                   
  55 to 64                                                                −**0.0955**                                        0.0132                                                \<0.0001                               −**0.0192**   0.0273        \<0.0001   **0.0424**    0.0119   \<0.0001
  65+                                                                     −**0.5977**                                        0.012                                                 −**0.7795**                            0.0269        −**0.0967**   0.0109                            
  Metropolitan Statistical Area                                           **0.0586**                                         0.0111                                                \<0.0001                               −0.0436       0.0282        0.1218     **0.0732**    0.0103   \<0.0001
  Female                                                                  0.0132                                             0.0082                                                0.1068                                 **0.0536**    0.0204        0.0087     −**0.0253**   0.0079   0.0014
  Geographic Region (vs Northeast)                                                                                                                                                                                                                                                      
  North Central                                                           −**0.2087**                                        0.0134                                                \<0.0001                               −**0.1533**   0.0329        \<0.0001   −**0.1483**   0.0133   \<0.0001
  West                                                                    **0.1261**                                         0.0153                                                **0.3305**                             0.0362        **0.0171**    0.0145                            
  South                                                                   −**0.0824**                                        0.0136                                                −**0.0661**                            0.0329        −**0.063**    0.0132                            
  Year of Stroke Diagnosis (vs 2006)                                                                                                                                                                                                                                                    
  2007                                                                    0.0274                                             0.0134                                                \<0.0001                               0.0687        0.034         0.0707     0.0022        0.013    \<0.0001
  2008                                                                    **0.0665**                                         0.0134                                                **0.1376**                             0.0341        −0.0084       0.013                             
  2009                                                                    **0.0925**                                         0.013                                                 **0.12**                               0.0324        0.0237        0.0126                            
  2010                                                                    **0.0396**                                         0.0131                                                **0.0862**                             0.033         0.0087        0.0129                            
  2011                                                                    0.0682                                             0.029                                                 0.0789                                 0.0715        −**0.1114**   0.0309                            
  OAC use                                                                 −0.0016                                            0.0158                                                0.918                                  −0.0242       0.0369        0.5122     −**0.0889**   0.0159   \<0.0001
  Selected Comorbidities                                                                                                                                                                                                                                                                
  Acute MI                                                                **0.1037**                                         0.0343                                                0.0025                                 0.164         0.1009        0.1041     0.0711        0.0335   0.0336
  CHF                                                                     0.0027                                             0.0158                                                0.8629                                 **0.1395**    0.0466        0.0027     **0.0475**    0.0162   0.0034
  CKD                                                                     **0.0646**                                         0.0231                                                0.0052                                 −0.0743       0.0672        0.2691     **0.1763**    0.025    \<0.0001
  COPD                                                                    −0.0216                                            0.0145                                                0.1343                                 −0.0369       0.0416        0.3745     0.0153        0.014    0.2742
  Diabetes mellitus                                                       **0.036**                                          0.0094                                                0.0001                                 0.0209        0.0276        0.4495     **0.1089**    0.0095   \<0.0001
  Hypertension                                                            0.0152                                             0.0084                                                0.0721                                 0.0257        0.0219        0.2412     **0.0443**    0.0082   \<0.0001
  Liver disease                                                           0.0061                                             0.0294                                                0.8345                                 0.0309        0.0601        0.6067     **0.1147**    0.0263   \<0.0001
  Malignancy                                                              −0.0263                                            0.0123                                                0.0327                                 −0.0388       0.0323        0.2293     0.0179        0.0119   0.1314
  Peripheral vascular                                                     **0.0367**                                         0.0142                                                0.0098                                 0.0009        0.042         0.9828     **0.0607**    0.0142   \<0.0001
  All‐Cause Baseline Resource Use                                                                                                                                                                                                                                                       
  Had hospitalization                                                     0.028                                              0.011                                                 0.0109                                 −**0.0818**   0.0288        0.0045     **0.0401**    0.0106   0.0002
  Had ED visit in baseline                                                **0.0368**                                         0.0109                                                0.0008                                 −0.0454       0.0275        0.0984     **0.0489**    0.0099   \<0.0001

Note: Bolded parameters are significant (*P*\<0.01). AF indicates atrial fibrillation; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; OAC, oral anticoagulant.

N=46 071; ratio of deviance to degrees of freedom=1.1185.

N=10 010; ratio of deviance to degrees of freedom=1.1574.

N=39 560; ratio of deviance to degrees of freedom=1.0977.

Source: Truven MarketScan^®^ Research Databases January 1, 2005 to December 31, 2011.

Discussion
==========

In this study, we estimate the direct cost of stroke‐related medical care among patients with AF versus those without AF using a large payer database. After controlling for potential confounders, adjusted mean incremental costs (index plus 12‐month post‐index) for AF patients were significantly higher than those for non‐AF patients, with results from a generalized linear model demonstrating the statistical significance of this relationship. This study is subject to the general limitations of basing case ascertainment on ICD‐9‐CM codes from billing data, including coding errors and potential underestimation of event occurrence. We only counted follow‐up costs for medical care that listed stroke/TIA as a diagnosis; also, this likely underestimates the full costs experienced by patients, because some stroke‐related services may be coded for specific complications rather than strictly stroke or TIA. However, our index hospitalization and post‐index stroke‐related cost findings are consistent with estimates reported from previous studies using various sources of data.^[@b3],[@b10]^

While limited data exist on the relationship between AF and stroke‐related costs from a US perspective, multiple published studies have attempted to evaluate this relationship with non‐US data sources. For instance, a 2008 article published by Ghatnekar and colleagues evaluated the impact of AF on stroke‐related inpatient costs over a 3‐year follow‐up period in Sweden.^[@b11]^ Due to a higher observed mortality rate during the index stroke hospitalization, patients with AF had a shorter mean follow‐up period than those without the disease, resulting in a non‐significant difference in costs between the 2 cohorts over the full follow‐up period. The effect of AF on stroke‐related inpatient costs became statistically significant once only patients surviving the index event were included in the regression analysis (€818 higher, *P*\<0.01), a criterion also employed in our study. An analysis of data from the Berlin Acute Stroke Study also established a significant relationship between the presence of AF and higher total direct costs within 1 year of an index stroke event (€2982 higher, *P*\<0.001), with resource use and cost data obtained from a patient self‐report survey.^[@b12]^ In addition to providing data from a US perspective, our study adds to this body literature by providing estimates on stroke‐related costs for all components of medical care (eg, inpatient, outpatient, rehabilitation) to third‐party payers stratified by stroke type.

Our findings provide current estimates of the cost of various stroke types, including ischemic stroke, hemorrhagic stroke, and TIA. These results demonstrate the high economic burden of stroke to payers, especially in persons with AF. Therefore, reducing the risk of AF‐related stroke may be important from both a clinical and economic standpoint. Professional guidelines recommend oral anticoagulant therapy for the prevention of stroke in patients with AF.^[@b13]^ Data from this analysis will be useful when evaluating the cost‐effectiveness of clinical interventions designed to prevent stroke among those with AF, such as new developments in anticoagulant therapy.
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